FrancophonIA/ELRC3.0 huggingface dataset:
English: Malignancies and lymphoproliferative disorders
Maltese: Tumuri malinni u disturbi limfoproliferattivi
English: In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with etanercept developed injection site reactions compared with 3.4% of placebo-treated patients during the first 12 weeks of treatment.
Maltese: Fi provi kkontrollati f'pazjenti bi psorjasi tal-plakka, bejn wieħed u ieħor 13.6% tal-pazjenti kkurati b'etanercept żviluppaw reazzjonijiet fis-siti tal-injezzjoni meta mqabbla ma' 3.4% tal-pazjenti kkurati bil-plaċebo waqt l-ewwel 12-il ġimgħa tal-kura.
English: Inflammatory bowel disease (IBD) and uveitis in patients with juvenile idiopathic arthritis (JIA) There have been reports of IBD and uveitis in JIA patients being treated with etanercept (see section
Maltese: Mard infjammatorju tal-imsaren (IBD) u uveite f'pazjenti b'artrite idjopatika taż-żgħażagħ (JIA) Kien hemm rapporti ta' IBD u uveite f'pazjenti b'JIA li kienu qed jiġu kkurati b'etanercept (ara sezzjoni 4.8).
English: Etanercept was significantly better than placebo in all measures of disease activity (p < 0.001), and responses were similar with and without concomitant methotrexate therapy.
Maltese: Etanercept kien b'mod sinifikanti aħjar mill-plaċebo meta tkejlet l-attività tal-marda (p < 0.001), u r-risponsi kienu simili bi jew mingħajr it-terapija fl-istess ħin b'methotrexate.
English: Responses at Week 12
Maltese: a ġimgħ a 12
English: Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNFantagonists, including etanercept.
Maltese: Kanċer tal-ġilda melanoma u mhux melanoma (NMSC) kienu rrappurtati f'pazjenti kkurati b'antagonisti ta' TNF, li jinkludu etanercept.
English: Biogen Spain, S.L.
Maltese: Samsung BioLogics Co., Ltd.
English: In one study in children with juvenile idiopathic arthritis aged 4 to 17 years, 43 of 69 (62%) children experienced an infection while receiving etanercept during 3 months of the study (part 1, open-label), and the frequency and severity of infections was similar in 58 patients completing 12 months of openlabel extension therapy.
Maltese: Fi studju fi tfal b'artrite idjopatika taż-żgħażagħ li għandhom minn 4 sa 17-il sena, 43 mid-69 (62%) tat-tfal li kienu fuq il-kura b'etanercept kellhom infezzjoni matul it-3 xhur tal-istudju (l-ewwel parti open-label), u l-frekwenza u s-severità tal-infezzjoni kienu simili fi 58 pazjent li spiċċaw it-12-il xahar ta' terapija open-label ta' estensjoni.
English: The recommended dose is 0.4 mg/kg (up to a maximum of 25 mg per dose), given twice weekly as a subcutaneous injection with an interval of 3-4 days between doses or 0.8 mg/kg (up to a maximum of 50 mg per dose) given once weekly.
Maltese: Id-doża rakkomandata hi ta' 0.4 mg/kg (sa massimu ta' 25 mg kull doża), mogħtija darbtejn f'ġimgħa bħala injezzjoni taħt il-ġilda b'intervall ta' 3-4 ijiem bejn id-dożi jew 0.8 mg/kg (sa massimu ta' 50 mg kull doża) mogħtija darba fil-ġimgħa.
English: Solution for injection Multipack: 12 (3 packs of 4) pre-filled syringes
Maltese: Pakkett multiplu: 12-il (3 pakketti ta' 4) siringa mimlija għal-lest.
English: Each pen contains 50 mg etanercept.
Maltese: Kull pinna fiha 50 mg ta' etanercept.
English: Responses of patients with psoriatic arthritis in a placebo-controlled trial
Maltese: Risponsi ta' pazjenti b'artrite psorjatika fi prova kkontrollata bil-plaċebo
English: Pregnancy
Maltese: konvulżjoni
English: Class
Maltese: Tilqim
English: Τηλ: + 357 22 00 04 93
Maltese: Genesis Pharma (Cyprus) Ltd Τηλ: + 357 22 00 04 93
English: The safety and efficacy profiles of the 50 mg once-weekly and 25 mg twice-weekly regimens were similar.
Maltese: Il-profili tas-sigurta u l-effikaċja tal-korsijiet ta' 50 mg darba fil-ġimgħa jew ta' 25 mg darbtejn fil-ġimgħa kienu simili.
English: Neoplasms benign, malignant and
Maltese: Neoplażmi beninni, malinni u dawk mhux
English: This section presents data from four randomised controlled trials in adults with rheumatoid arthritis, one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis, one study in adults with non-radiographic axial spondyloarthritis, four studies in adults with plaque psoriasis, three studies in juvenile idiopathic arthritis and one study in paediatric patients with plaque psoriasis.
Maltese: Din is-sezzjoni fiha tagħrif meħud minn erba' studji randomised u kkontrollati f'adulti b'artrite rewmatojde, studju wieħed f'adulti b'artrite psorjatika, studju wieħed f'adulti b'ankylosing spondylitis, studju wieħed f'adulti bi spondiloartrite assjali mhux radjografika, erba' studji f'adulti bi psorjasi tal-plakka, tliet studji dwar artrite idjopatika taż-żgħażagħ u studju wieħed fuq pazjenti pedjatriċi bi psorjasi tal-plakka.
English: Concurrent treatment with sulfasalazine
Maltese: Il-kura fl-istess ħin ma' sulfasalazine
English: Injection site reactions (including bleeding, bruising, erythema, itching, pain, swelling)*
Maltese: Infezzjoni (inklużi infezzjoni fis-sistema respiratorja ta' fuq, bronkite, ċistite, infezzjoni tal-ġilda)*
English: These are rare or uncommon side effects, but are serious conditions (some of which may rarely be fatal).
Maltese: Dawn huma effetti rari jew mhux komuni, imma huma kundizzjonijiet serji (fejn xi wħud jistgħu rarement ikunu fatali).
English: Etanercept may also modulate biologic responses controlled by additional downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or regulated by TNF.
Maltese: Etanercept jista' wkoll jimmodula r-risponsi bijoloġiċi kkontrollati b'molekuli addizzjonali downstream (eż. cytokines, molekuli tal-adeżjoni jew proteinases) li huma kkaġunati jew irregolati mit-TNF.
English: The efficacy of etanercept was assessed in a randomised, double-blind, placebo-controlled study in 205 patients with psoriatic arthritis.
Maltese: Fi studju kliniku randomised, double blind, ikkontrollat bil-plaċebo f'pazjenti adulti b'artrite psorjatika,
English: Study 1 was a Phase 2 study in patients with active, but clinically stable, plaque psoriasis involving ≥ 10% of the body surface area who were ≥ 18 years old.
Maltese: 2 f'pazjenti bi psorjasi tal-plakka klinikament stabbli imma attiva li tinvolvi ≥ 10% tal-erja tal-wiċċ tal-ġisem li kellhom ≥ 18-il sena.
English: TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on cross-linking of cell surface TNFRs.
Maltese: TNF u lymphotoxin jeżistu l-aktar bħala homotrimers, bl-attività bijoloġika tagħhom li hi dipendenti fuq cross-linking ma' TNFRs fuq is-superfiċje taċ-ċelluli.
English: Benepali is not recommended for the treatment of Wegener's granulomatosis.
Maltese: Benepali mhuwiex rakkomandat għall-kura ta' granulomatożi ta' Wegener.
English: Autoantibody formation Treatment with Benepali may result in the formation of autoimmune antibodies (see section 4.8).
Maltese: Il-kura b'Benepali tista' tirriżulta fil-formazzjoni ta' antikorpi awtoimmunitarji (ara sezzjoni 4.8).
English: Treatment of active and progressive psoriatic arthritis in adults when the response to previous diseasemodifying antirheumatic drug therapy has been inadequate.
Maltese: Il-kura ta' artrite psorjatika attiva u progressiva f'adulti meta r-rispons ma kienx adegwat meta ngħataw terapija b'mediċini anti-rewmatiċi li jimmodifikaw il-marda.
English: A risk for the development of malignancies in children and adolescents treated with TNF-antagonists cannot be excluded.
Maltese: Ma jistax jiġi eskluż riskju li jiżviluppaw tumuri malinni fi tfal u adolexxenti li jkunu kkurati b'antagonisti ta' TNF.
English: MTX Etanercept 25 mg
Maltese: Kull siringa mimlija għal-lest fiha 25 mg ta' etanercept.
English: Overall, infections were more commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus 2%), and the infections associated with etanercept use were of a more severe nature.
Maltese: B'mod ġenerali, l-infezzjonijiet ġew irrapportati b'mod iktar komuni f'pazjenti kkurati b'etanercept meta mqabbel ma' methotrexate waħdu (3.8 kontra 2%), u l-infezzjonijiet assoċjati mal-użu ta' etanercept kienu ta' natura aktar severa.
English: The disability index score was significantly improved at all timepoints in psoriatic arthritis patients treated with etanercept, relative to placebo (p < 0.001).
Maltese: Il-punteġġ tal-indiċi taddiżabilità kien b'mod sinifikanti aħjar f'kull punt ta' żmien f'pazjenti bl-artrite psorjatika kkurati b'etanercept, meta mqabbel mal-plaċebo (p < 0.001).
English: Elevated liver enzymes*
Maltese: Żieda fl-enzimi tal-fwied*
English: The primary measure of efficacy (ASAS 40) was a 40% improvement in at least three of the four ASAS domains and absence of deterioration in the remaining domain.
Maltese: Il-miżura ewlenija tal-effikaċja (ASAS 40) kienet titjib ta' 40% f'mill-inqas tlieta mill-erba' oqsma ASAS u nuqqas ta' deterjorament fil-qasam li fadal.
English: • Uncommon (may affect up to 1 in 100 people):
Maltese: • Mhux komuni (jistgħu jaffettwaw sa persuna 1 minn kull 100):
English: wk 12 wk wk
Maltese: TAGĦRIF
English: -0.03 (0.09)a
Maltese: (p < 0.001).
English: lymphoma, leukaemia
Maltese: Kankrijiet tal-ġilda
English: In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of 4 years at time of enrolment) continued to receive etanercept for up to 10 years.
Maltese: Fi studju ta' estensjoni tas-sigurtà bit-tikketta mikxufa, 58 pazjent pedjatriku mill-istudju ta' hawn fuq (mill-età ta' 4 snin fi żmien ir-reġistrazzjoni) baqgħu jirċievu etanercept sa 10 snin.
English: Subcutaneous use.
Maltese: • artrite psorjatika;
English: In long-term (up to 34 months) open-label studies where etanercept was given without interruption, clinical responses were sustained and safety was comparable to shorter-term studies.
Maltese: Fi studji open-label fit-tul (li damu sa 34 xahar) fejn etanercept ingħata mingħajr interruzzjoni, irrisponsi kliniċi kienu sostnuti u s-sigurtà kienet komparabbli ma' dik fi studji li damu inqas żmien.
English: Patient Alert Card Benepali Etanercept
Maltese: Kard ta' Allert tal-Pazjent Benepali Etanercept
English: Non-melanoma skin cancers* (see section 4.4)
Maltese: Kankrijiet talġilda li mhumiex melanoma* (ara sezzjoni 4.4).
English: Pruritus, rash Angioedema, psoriasis (including new onset or worsening and pustular, primarily palms and soles), urticaria, psoriasiform rash
Maltese: Ħakk, raxx Anġjoedema, psorjasi (li tinkludi bidu millġdid jew aggravament ta' psorjasi, u psorjasi bil-ponot, primarjament filkeffa tal-id u filqiegħ tas-saqajn), urtikarja, raxx, psorjasiformi
English: In clinical studies, concurrent administration of abatacept and etanercept resulted in increased incidences of serious adverse events.
Maltese: Fi studji kliniċi, l-għoti ta' abatacept u etanercept fl-istess ħin irriżulta f'żieda ta' inċidenzi ta' avvenimenti avversi serji.
English: However, limited safety data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar to that seen in adults and children aged 4 years and older, when dosed every week with 0.8 mg/kg subcutaneously (see section 5.1).
Maltese: Madankollu, tagħrif limitat dwar issigurtà minn reġistru ta' pazjent jissuġġerixxi li l-profil tas-sigurtà fi tfal minn sentejn sa 3 snin huwa simili għal dak li jidher fl-adulti u tfal minn 4 snin 'il fuq, meta ddożati kull ġimgħa b'0.8 mg/kg taħt il-ġilda (ara sezzjoni 5.1).
English: Patients were between 18 and 70 years of age and had active psoriatic arthritis (≥ 3 swollen joints and ≥ 3 tender joints) in at least one of the following forms: (1)
Maltese: Il-pazjenti kellhom bejn 18 u 70 sena u kellhom artrite psorjatika attiva (≥ 3 ġogi minfuħin u ≥ 3 ġogi sensittivi) f'mill-anqas waħda minn dawn il forom:
English: Doctor's phone:
Maltese: Sími:
English: Allow the medicine to reach room temperature:
Maltese: Ħalli l-mediċina tilħaq it-temperatura tal-kamra:
English: *Some patients did not provide complete data for each endpoint **ASAS=Assessments in Spondyloarthritis International Society ***Bath Ankylosing Spondylitis Disease Activity Index a: p < 0.001, b: < 0.01 and c: < 0.05, respectively between etanercept and placebo
Maltese: * Xi pazjenti ma pprovdewx dejta sħiħa għal kull endpoint **ASAS=Soċjetà Internazzjonali ta' Evalwazzjonijiet ta' Spondiloartrite ***Indiċi ta' Attività tal-Marda Spondilite Ankilosing ta' Bath : p < 0.001,
English: Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis including ankylosing spondylitis The usual dose is 50 mg once a week as an injection under the skin.
Maltese: Wara li toħroġ is-siringa mill-friġġ, stenna madwar 30 minuta biex tippermetti lis-soluzzjoni ta' Benepali fis-siringa tilħaq it-temperatura tal-kamra.
English: Psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis The recommended dose is 50 mg etanercept administered once weekly.
Maltese: Il-kura f'adulti li għandhom ankylosing spondylitis severa u attiva u li kellhom rispons mhux adegwat għat-terapija konvenzjonali.
English: This card contains important safety information that you need to be aware of before you are given Benepali and during treatment with Benepali.
Maltese: Din il-card fiha informazzjoni importanti dwar is-sigurtà li inti jeħtieġ li tkun taf dwarha qabel ma tingħata Benepali u matul il-kura b'Benepali.
English: • Rare (may affect up to 1 in 1,000 people):
Maltese: • Rari (jistgħu jaffettwaw sa persuna 1 minn kull 1,000):
English: Paediatric plaque psoriasis (age 6 years and above) The recommended dose is 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly for up to 24 weeks.
Maltese: Id-doża rakkomandata hi ta' 0.8 mg/kg (sa massimu ta' 50 mg kull doża) darba fil-ġimgħa għal sa 24 ġimgħa.
English: In patients who develop HBV infection, Benepali should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.
Maltese: F'pazjenti li jiżviluppaw infezzjoni tal-HBV, Benepali għandu jitwaqqaf u għandha tinbeda terapija antivirali effettiva b'kura adatta ta' appoġġ.
English: The usual dose range is between 5 and 20 mg per day.
Maltese: Id-doża normali tvarja bejn 5 u 20 mg kuljum.
English: It is available as white, round film-coated tablets (2.5, 5, 7.5 and 10 mg) and yellow, round orodispersible tablets (5, 10, 15 and 20 mg).
Maltese: Hija disponibbli bħala pilloli tondi bojod miksija b'rita (2.5, 5, 7.5 u 10 mg) u pilloli tondi sofor li jdubu fil-ħalq (5, 10, 15 u 20 mg).
English: This summary was last updated in 04-2010.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar fi 04-2010.
English: The active substance in Olanzapine Apotex, olanzapine, is an antipsychotic medicine.
Maltese: Is-sustanza attiva f'Olanzapine Apotex, olanzapine, hija mediċina antipsikotika.
English: The recommended starting dose of Olanzapine Apotex depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day.
Maltese: Doża ta' 10 mg kuljum tintuża għall-iskizofrenija u fil-prevenzjoni ta' episodji manijaċi, u 15 mg kuljum fit-trattament ta' episodji manijaċi, sakemm ma tintużax ma' mediċini oħra, f'liema każ id-doża talbidu tista' tkun ta' 10 mg kuljum.
English: It is thought that olanzapine's beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytrypamine (also called serotonin) and dopamine.
Maltese: Hu maħsub li l-effett benefiku tal-olanzapina huwa dovut għall-imblokkar tar-riċetturi għannewrotrasmettituri 5-idrossitriptamina (5-hydroxytrypamine, imsejħa wkoll serotonina) u dopamina.
English: This means that Olanzapine Apotex is similar to ‘reference medicines' already authorised in the European Union (EU) called Zyprexa and Zyprexa Velotab.
Maltese: Olanzapine Apotex huwa ‘mediċina ġenerika' Dan ifisser li Olanzapine Apotex hija simili għall-‘mediċini ta' referenza' diġà awtorizzati fl-Unjoni Europea (UE) li jisimhom Zyprexa u Zyprexa Velotab.
English: This document is a summary of the European Public Assessment Report (EPAR) for Olanzapine Apotex.
Maltese: Dan id-dokument huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Olanzapine Apotex.
English: Olanzapine Apotex is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
Maltese: Olanzapine Apotex jintuża wkoll fit-trattament ta' episodji moderati jew severi tal-manija (burdata tajba b'mod estrem) f'adulti.
English: The European Commission granted a marketing authorisation valid throughout the EU for Olanzapine Apotex to Apotex Europe B.V. on 10 June 2010.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida madwar l-Unjoni Ewropea kollha għal Olanzapine Apotex lil Apotex Europe B.V. fil-10 ta' Ġunju 2010.
English: Schizophrenia is a mental illness that has a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs).
Maltese: Din hija marda mentali, li għandha numru ta' sintomi, inkluż disturbi fil-ħsieb u fid-diskors, alluċinazzjonijiet (jiġifieri d-dehra u s-smigħ ta' affarijiet li jkunu immaġinarji), suspetti u delirji (thewdin żbaljat).
English: The CHMP concluded that, in accordance with EU requirements, Olanzapine Apotex has been shown to have comparable quality and to be bioequivalent to Zyprexa and Zyprexa Velotab.
Maltese: Is-CHMP kkonkluda li, b'mod konformi mar-rekwiżiti tal-UE, Olanzapine Apotex wera li għandu kwalità komparabbli ma' u huwa bijoekwivalenti għal Zyprexa u Zyprexa Velotab.
English: For more information on generic medicines, see the question-and-answer document here.
Maltese: Għallaktar informazzjoni dwar il-mediċini ġeneriċi, ara d-dokument mistoqsija-u-tweġiba hawn.
English: Therefore, the CHMP's view was that, as for Zyprexa and Zyprexa Velotab, the benefit outweighs the identified risk.
Maltese: Għaldaqstant, il-fehma tasCHMP kienet li, bħal Zyprexa and Zyprexa Velotab, il-benefiċċju jegħleb r-riskju identifikat.
English: It is known as an ‘atypical' antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s.
Maltese: Hija magħrufa bħala antipsikotiku ‘atipiku' minħabba li hija differenti mill-mediċini antipsikotiċi iktar antiki li ilhom disponibbli mill-ħamsinijiet.
English: Olanzapine Apotex is a medicine containing the active substance olanzapine.
Maltese: Olanzapine Apotex hija mediċina li fiha s-sustanza attiva olanzapine.
English: Because Olanzapine Apotex is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicines.
Maltese: Billi Olanzapine Apotex huwa mediċina ġenerika, l-istudji ġew limitati għal testitjiet biex jiddeterminaw il-bijoekwivalenza tiegħu mal-mediċini ta' referenza.
English: This disrupts signals transmitted between brain cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other.
Maltese: Dan ifixkel sinjali trasmessi bejn iċċelluli tal-moħħ minn ‘newrotrasmettituri', kimiċi li jippermettu liċ-ċelluli ta' nervituri jikkomunikaw ma' xulxin.
English: What is Olanzapine Apotex?
Maltese: X'inhu Olanzapine Apotex?
English: Patients over 65 years of age and patients who have problems with their liver or kidneys may need a lower starting dose of 5 mg per day.
Maltese: Il-pazjenti li jkollhom iktar minn 65 sena u pazjenti li jkollhom problemi fil-fwied jew filkliewi tagħhom jista' jkollhom bżonn ta' doża iktar baxxa fil-bidu 5 mg kuljum.
English: Since these neurotransmitters are involved in schizophrenia and in bipolar disorder, olanzapine helps to normalise the activity of the brain, reducing the symptoms of these diseases.
Maltese: Billi dawn in-newrotrażmettituri għandhom sehem fl-iskizofrenija u fid-disturbi bipolari, olanzapine jgħin fin-normalizzazzjoni tal-attività tal-moħħ, u b'hekk inaqqas is-sintomi ta' dawn il-mardiet.
English: Why has Olanzapine Apotex been approved?
Maltese: Għaliex ġie approvat Olanzapine Apotex?
English: Because Olanzapine Apotex is a generic medicine and is bioequivalent to the reference medicines, its benefit and risk are taken as being the same as the reference medicines'.
Maltese: Minħabba li Olanzapine Apotex huwa mediċina ġenerika u hija bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċju u r-riskju tiegħu huma meqjusa li huma l-istess bħal dawk tal-mediċina ta' referenza.
English: How has Olanzapine Apotex been studied?
Maltese: Kif ġie studjat Olanzapine Apotex?
English: United Kingdom Clinigen Healthcare Ltd. Pitcairn House, Crown Square First Avenue, Burton-on-Trent, Staffordshire, DE14 2WW
Maltese: Ir-Renju Unit
English: Czech Republic
Maltese: Ir-Repubblika Ċeka
English: Italy
Maltese: L-Italja
English: The full EPAR for Ocrevus can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Ocrevus.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Ocrevus.
English: In two studies of 1,656 patients with relapsing forms of multiple sclerosis (RMS), the average number of relapses in patients treated with Ocrevus was about half that in patients treated with another medicine interferon beta-1a (0.16 versus 0.29 relapses per year).
Maltese: F'żewġ studji ta' 1,656 pazjent b'forom rikaduti tal-isklerożi multipla (RMS), in-numru medju ta' rikaduti f'pazjenti kkurati b'Ocrevus kien madwar nofs dak f'pazjenti kkurati b'mediċina oħra ta' interferon beta-1a (0.16 kontra 0.29 rikaduti fis-sena).
English: • adults with primary progressive multiple sclerosis (PPMS), where symptoms get steadily worse over time.
Maltese: • adulti bi sklerożi multipla progressiva primarja (PPMS), fejn is-sintomi jiggravaw b'mod stabbli maż-żmien.
English: Why is Ocrevus approved?
Maltese: Għaliex ġie approvat Ocrevus?
English: A third study, in 732 patients with primary progressive multiple sclerosis (PPMS), showed that fewer patients taking Ocrevus had worsening symptoms lasting 12 weeks or more (30%) compared with those taking a placebo (34%).
Maltese: It-tielet studju, fuq 732 pazjent bi sklerożi multipla progressiva primarja (PPMS), wera li inqas pazjenti li kienu qed jieħdu Ocrevus kellhom sintomi li ggravaw li damu 12-il ġimgħa jew aktar (30%) meta mqabbla ma' dawk li kienu qed jieħdu plaċebo (34%).
English: Studies showed that Ocrevus was more effective than interferon beta-1a at reducing the number of relapses in patients with relapsing forms of multiple sclerosis.
Maltese: L-istudji wrew li Ocrevus kien aktar effettiv minn interferon beta-1a biex inaqqas in-numru ta' rikaduti f'pazjenti b'forom rikaduti tal-isklerożi multipla.
English: These occur in more than 1 in 10 people.
Maltese: Dawn iseħħu f'aktar minn 1 minn kull 10 persuni.
English: Ocrevus is a medicine for treating multiple sclerosis - an inflammatory disease of the nervous system that causes symptoms such as weakness, difficulty walking and problems with vision.
Maltese: Ocrevus huwa mediċina għall-kura tal-isklerożi multipla - marda infjammatorja tas-sistema nervuża li tikkawża sintomi bħal dgħufija, diffikultà biex timxi u problema fil-vista.
English: Ocrevus contains the active substance ocrelizumab.
Maltese: Ocrevus fih is-sustanza attiva ocrelizumab.
English: The active substance in Ocrevus, ocrelizumab, is a monoclonal antibody designed to recognise and attach to a target called CD20 on the surface of certain types of white blood cells (so called B cells).
Maltese: Is-sustanza attiva f'Ocrevus, l-ocrelizumab, hija antikorp monoklonali mfassla biex tagħraf u teħel ma' mira msejħa CD20 fuq il-wiċċ ta' ċerti tipi ta' ċelloli bojod tad-demm (dawk imsejħa ċelloli B).
English: Other information about Ocrevus
Maltese: Informazzjoni oħra dwar Ocrevus
English: What are the risks associated with Ocrevus?
Maltese: X'inhuma r-riskji assoċjati ma' Ocrevus?